As the use of the Accu-Chek Aviva Expert bolus advisor for people using Multiple Daily Injections (MDI) becomes more widespread, a new survey report outlines the positive effects of the system on patients’ confidence and quality of life.1
A clinical paper published in January studied the attitudes and behaviours of a group of nearly 600 people with Type 1 diabetes towards insulin therapy following a four-week trial use of the Accu-Chek Aviva Expert system (an integrated bolus advisor and blood glucose monitor).
For people on insulin, one of the greatest worries of self-management is the underlying fear of having a hypo. When you have diabetes you quickly learn that hypos are best avoided.
The report concluded that most respondents felt using a bolus advisor was much easier than manual bolus calculation, improving their confidence in the accuracy of their insulin bolus and reducing their fear of hypos. As many as 52% of the people in the trial reported a reduction, or significant reduction, in their fear of hypos.
Following use of the Accu-Chek Aviva Expert system, the report showed that most people expressed a marked improvement in their ability to achieve blood glucose targets, with significant reductions in HbA1c levels being mentioned spontaneously by some people. There was also a positive impact on quality of life and 72% reported an enhanced overall sense of well-being.
1. Katharine Barnard et al, Journal of Diabetes Science and Technology, January 2012, Volume 6, Issue 1: pages 144-149. Patient comments: Data on file, Roche Diagnostics, UK.
To fine out more, click here.